Brasofensine (NS-2214 BMS-204756) is a phenyltropane that had been under development for the treatment of Parkinson’s and Alzheimer’s disease. Phase II trials were conducted in 1996 and brasofensine was shown to be both effective and well tolerated at a dose of 4 mg however development was stopped after in vivo cis-anti isomerization of the 2α-methyloxime group was reported.
This page contains content from the copyrighted Wikipedia article "Brasofensine"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
